Effect of estrogen on cerebrovascular prostaglandins is amplified in mice with dysfunctional NOS

Xiangduan Li, Greg G. Geary, Rayna J Gonzales, Diana N. Krause, Sue P. Duckles

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Chronic estrogen treatment increases endothelial vasodilator function in cerebral arteries. Endothelial nitric oxide (NO) synthase (eNOS) is a primary target of the hormone, but other endothelial factors may be modulated as well. In light of possible interactions between NO and prostaglandins, we tested the hypothesis that estrogen treatment increases prostanoid-mediated dilation using NOS-deficient female mouse models, i.e., mice treated with a NOS inhibitor [NG-nitro-L-arginine methyl ester (L-NAME)] for 21 days or transgenic mice with the eNOS gene disrupted (eNOS-/-). All mice were ovariectomized; some in each group were treated chronically with estrogen. Cerebral blood vessels then were isolated for biochemical and functional analyses. In vessels from control mice, estrogen increased protein levels of eNOS but had no significant effect on cyclooxygenase (COX)-I protein, prostacyclin production, or constriction of pressurized, middle cerebral arteries to indomethacin, a COX inhibitor. In L-NAME-treated mice, however, cerebrovascular COX-1 levels, prostacyclin production, and constriction to indomethacin, as well as eNOS protein, were all greater in estrogen-treated animals. In vessels from eNOS-/- mice, estrogen treatment also increased levels of COX-1 protein and constriction to indomethacin, but no effect on prostacyclin production was detected. Thus cerebral blood vessels of control mice did not exhibit effects of estrogen on the prostacyclin pathway. However, when NO production was dysfunctional, the impact of estrogen on a COX-sensitive vasodilator was revealed. Estrogen has multiple endothelial targets; estrogen effects may be modified by interactions among these factors.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume287
Issue number2 56-2
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Prostaglandins
Estrogens
Epoprostenol
NG-Nitroarginine Methyl Ester
Constriction
Indomethacin
Cyclooxygenase 1
Prostaglandin-Endoperoxide Synthases
Vasodilator Agents
Blood Vessels
Nitric Oxide
Proteins
Cerebral Arteries
Cyclooxygenase Inhibitors
Nitric Oxide Synthase Type III
Middle Cerebral Artery
Transgenic Mice
Dilatation
Hormones
Genes

Keywords

  • Cyclooxygenase-1
  • Endothelial nitric oxide synthase
  • Indomethacin
  • N-nitro-L-arginine methyl ester
  • Prostacyclin

ASJC Scopus subject areas

  • Physiology

Cite this

Effect of estrogen on cerebrovascular prostaglandins is amplified in mice with dysfunctional NOS. / Li, Xiangduan; Geary, Greg G.; Gonzales, Rayna J; Krause, Diana N.; Duckles, Sue P.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 287, No. 2 56-2, 08.2004.

Research output: Contribution to journalArticle

@article{d797f2986e7245babfcb918a0bf84dec,
title = "Effect of estrogen on cerebrovascular prostaglandins is amplified in mice with dysfunctional NOS",
abstract = "Chronic estrogen treatment increases endothelial vasodilator function in cerebral arteries. Endothelial nitric oxide (NO) synthase (eNOS) is a primary target of the hormone, but other endothelial factors may be modulated as well. In light of possible interactions between NO and prostaglandins, we tested the hypothesis that estrogen treatment increases prostanoid-mediated dilation using NOS-deficient female mouse models, i.e., mice treated with a NOS inhibitor [NG-nitro-L-arginine methyl ester (L-NAME)] for 21 days or transgenic mice with the eNOS gene disrupted (eNOS-/-). All mice were ovariectomized; some in each group were treated chronically with estrogen. Cerebral blood vessels then were isolated for biochemical and functional analyses. In vessels from control mice, estrogen increased protein levels of eNOS but had no significant effect on cyclooxygenase (COX)-I protein, prostacyclin production, or constriction of pressurized, middle cerebral arteries to indomethacin, a COX inhibitor. In L-NAME-treated mice, however, cerebrovascular COX-1 levels, prostacyclin production, and constriction to indomethacin, as well as eNOS protein, were all greater in estrogen-treated animals. In vessels from eNOS-/- mice, estrogen treatment also increased levels of COX-1 protein and constriction to indomethacin, but no effect on prostacyclin production was detected. Thus cerebral blood vessels of control mice did not exhibit effects of estrogen on the prostacyclin pathway. However, when NO production was dysfunctional, the impact of estrogen on a COX-sensitive vasodilator was revealed. Estrogen has multiple endothelial targets; estrogen effects may be modified by interactions among these factors.",
keywords = "Cyclooxygenase-1, Endothelial nitric oxide synthase, Indomethacin, N-nitro-L-arginine methyl ester, Prostacyclin",
author = "Xiangduan Li and Geary, {Greg G.} and Gonzales, {Rayna J} and Krause, {Diana N.} and Duckles, {Sue P.}",
year = "2004",
month = "8",
doi = "10.1152/ajpheart.01176.2003",
language = "English (US)",
volume = "287",
journal = "American Journal of Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "2 56-2",

}

TY - JOUR

T1 - Effect of estrogen on cerebrovascular prostaglandins is amplified in mice with dysfunctional NOS

AU - Li, Xiangduan

AU - Geary, Greg G.

AU - Gonzales, Rayna J

AU - Krause, Diana N.

AU - Duckles, Sue P.

PY - 2004/8

Y1 - 2004/8

N2 - Chronic estrogen treatment increases endothelial vasodilator function in cerebral arteries. Endothelial nitric oxide (NO) synthase (eNOS) is a primary target of the hormone, but other endothelial factors may be modulated as well. In light of possible interactions between NO and prostaglandins, we tested the hypothesis that estrogen treatment increases prostanoid-mediated dilation using NOS-deficient female mouse models, i.e., mice treated with a NOS inhibitor [NG-nitro-L-arginine methyl ester (L-NAME)] for 21 days or transgenic mice with the eNOS gene disrupted (eNOS-/-). All mice were ovariectomized; some in each group were treated chronically with estrogen. Cerebral blood vessels then were isolated for biochemical and functional analyses. In vessels from control mice, estrogen increased protein levels of eNOS but had no significant effect on cyclooxygenase (COX)-I protein, prostacyclin production, or constriction of pressurized, middle cerebral arteries to indomethacin, a COX inhibitor. In L-NAME-treated mice, however, cerebrovascular COX-1 levels, prostacyclin production, and constriction to indomethacin, as well as eNOS protein, were all greater in estrogen-treated animals. In vessels from eNOS-/- mice, estrogen treatment also increased levels of COX-1 protein and constriction to indomethacin, but no effect on prostacyclin production was detected. Thus cerebral blood vessels of control mice did not exhibit effects of estrogen on the prostacyclin pathway. However, when NO production was dysfunctional, the impact of estrogen on a COX-sensitive vasodilator was revealed. Estrogen has multiple endothelial targets; estrogen effects may be modified by interactions among these factors.

AB - Chronic estrogen treatment increases endothelial vasodilator function in cerebral arteries. Endothelial nitric oxide (NO) synthase (eNOS) is a primary target of the hormone, but other endothelial factors may be modulated as well. In light of possible interactions between NO and prostaglandins, we tested the hypothesis that estrogen treatment increases prostanoid-mediated dilation using NOS-deficient female mouse models, i.e., mice treated with a NOS inhibitor [NG-nitro-L-arginine methyl ester (L-NAME)] for 21 days or transgenic mice with the eNOS gene disrupted (eNOS-/-). All mice were ovariectomized; some in each group were treated chronically with estrogen. Cerebral blood vessels then were isolated for biochemical and functional analyses. In vessels from control mice, estrogen increased protein levels of eNOS but had no significant effect on cyclooxygenase (COX)-I protein, prostacyclin production, or constriction of pressurized, middle cerebral arteries to indomethacin, a COX inhibitor. In L-NAME-treated mice, however, cerebrovascular COX-1 levels, prostacyclin production, and constriction to indomethacin, as well as eNOS protein, were all greater in estrogen-treated animals. In vessels from eNOS-/- mice, estrogen treatment also increased levels of COX-1 protein and constriction to indomethacin, but no effect on prostacyclin production was detected. Thus cerebral blood vessels of control mice did not exhibit effects of estrogen on the prostacyclin pathway. However, when NO production was dysfunctional, the impact of estrogen on a COX-sensitive vasodilator was revealed. Estrogen has multiple endothelial targets; estrogen effects may be modified by interactions among these factors.

KW - Cyclooxygenase-1

KW - Endothelial nitric oxide synthase

KW - Indomethacin

KW - N-nitro-L-arginine methyl ester

KW - Prostacyclin

UR - http://www.scopus.com/inward/record.url?scp=3242686081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242686081&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.01176.2003

DO - 10.1152/ajpheart.01176.2003

M3 - Article

VL - 287

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6143

IS - 2 56-2

ER -